Hemospray is not for sale in USA.

Simplifying Hemostasis

Learn More Learn More

All New Hemostasis Modality

Hemospray is a proprietary mineral blend powder developed specifically for endoscopic hemostasis. It contains no human or animal proteins or botanicals and has no known allergens. Hemospray is metabolically inert and deemed nontoxic, systemically or otherwise. Over the years, similar materials have been used by the military for topical battlefield hemostasis applications.

Easy as One, Two, Three

Easy as One, Two, Three

In just three easy steps you can deploy Hemospray to treat nonvariceal upper GI bleeds.

1. Simply activate the C02 cartridge
2. Open the valve
3. Spray toward the source of bleeding

An ease of use comparison was made for 84 patient treatments in a postmarket clinical registry and Hemospray was determined to be comparable to or easier than administration of other hemostasis treatment modalities.

Hemostasis was achieved in under 10 minutes in over 70% of cases with Hemospray. Hemospray was thought to save time in 59% of cases (57/97).

Contributors SEAL post market evaluation: University of Manitoba, Winnepeg MT, St. Pauls Hospital, Vancouver BC, St Michaels Hospital, Toronto ON, McGill University, Montreal QC, University Hospital Mainz, Germany, Queen Elizabeth Hospital, Birmingham, UK, Lund University Hospital, Malmo Sweden, Institute University Parc Tauli, Sabadell, Spain, Hvidovre Hospital, Copenhagen, Denmark, Hospital Cochin, Paris, France, Glasgow Royal Infirmary, Glasgow, Scotland, Erasmus Medical Center, Rotterdam, Netherlands, Ospedale San Paolo, Italy, Amsterdam Medical Center, Amsterdam Netherlands

“Hemospray is an important and novel therapy which offers an exciting new treatment option in patients at highest risk from bleeding lesions in the upper GI tract.”<br />
—John Morris, MD Glasgow Royal Infirmary, Glasgow, Scotland

“Hemospray is an important and novel therapy which offers an exciting new treatment option in patients at highest risk from bleeding lesions in the upper GI tract.”
—John Morris, MD Glasgow Royal Infirmary, Glasgow, Scotland

Video Library
Plus

Video Library

Reference Articles
Plus

Reference Articles

Training
Plus

Training